^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    inezetamab (AMG 994)

    i
    Other names: AMG 994
    Associations

    News

    Trials
    Company:
    Amgen, BeiGene
    Drug class:
    Mesothelin inhibitor, CD40 agonist
    Related drugs:
    Associations

    News

    Trials
    8ms
    Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=11, Completed, Amgen | Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Jun 2023
    Trial completion • Trial completion date • Combination therapy • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    inezetamab (AMG 994) • zeluvalimab (AMG 404)
    11ms
    Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Amgen | Trial completion date: Aug 2024 --> Sep 2023 | Trial primary completion date: Feb 2024 --> Jun 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    inezetamab (AMG 994) • zeluvalimab (AMG 404)
    over1year
    Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Amgen | Trial completion date: Mar 2023 --> Aug 2024 | Trial primary completion date: Jan 2023 --> Feb 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    inezetamab (AMG 994) • zeluvalimab (AMG 404)
    2years
    Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=214 --> 11 | Trial completion date: Aug 2025 --> Mar 2023 | Trial primary completion date: Feb 2025 --> Jan 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    inezetamab (AMG 994) • zeluvalimab (AMG 404)
    2years
    Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=214, Recruiting, Amgen | Trial primary completion date: Aug 2025 --> Feb 2025
    Trial primary completion date • Combination therapy
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    inezetamab (AMG 994) • zeluvalimab (AMG 404)
    over2years
    Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=214, Recruiting, Amgen | Trial completion date: Oct 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Aug 2025
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    inezetamab (AMG 994) • zeluvalimab (AMG 404)